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period of follow-back before HC); intensive care admissions (IA) was 0.3 ±  0.5 
nr/pt/year (while it was 0.9 ±  0.5 nr/pt/year during the same period of follow- 
back).
The presented data are consistent with a positive influence of HC on the clinical 
management in CHRF patients with hypercapnia. A possible cost saving could be 
also supposed. A revision o f  data from the Lombardy regional centers dealing with 
HC for these patients is in progress.
P2641
Oxygen Desaturation during  Sleep, Quality of Life and Compliance in 
Hypercapnie COPD Treated  with Nocturnal Nasal Ventilation at Home
C. Sturani, V. Galavotli, C. Scarduelli, G.P. Cordioli, A. Rosa, C. Perboni,
M. Bighellini, E. Politano. Division o f  Pneunwlogy, C. Poma Hospital, Mant ova - 
Italy
Few studies of nocturnal nasal ventilation (NNV) in COPD have been reported. 
Moreover, the quality of life (QOL) of COPD treated with home NNV has not 
been well described. To assess the compliance and the efficacy of NNV at home 
10 hypercapnie COPD (Pa02 48 mmHg, PaC02 53 mmHg, FEV1 0.74 L) were 
monitored during sleep and evaluated at home every 3 months for 1 year after 
the start of NNV (BiPAP ventilator). The Chronic Respiratory Disease Question­
naire (CRDQ) was administered as an assessment of QOL every 3 months by a 
respiratory therapist who was not concerned in other assessments, The results are 
reported in the table:
i monili 3 months 12 months
Mens, median use h 10.) (2) 9.8 (2) 7,2 (3.4)
Mean night Sa02% 90.7 (2,3) 92.8 (2.5)+ 89.9 (3)
Mean S«02 + 90% 67.9 (27) 78 (36)+ 61 (25)
Mean L Sa02% 75.8 (7.4) 80.8 (5.1) 76.1 (7)
CRDQ dyspnea 6.9 (1.3) 4.9 (1,5)+ 6.2 (1.6)
CRDQ fatigue 7.7 (1.5) 5.6 (1.1)+ 6.6 (1.2)
CRDQ mastery 5.9 (1.2) 6.1 (1,4)+ 5 (i,5)'H’
CRDQ emotion 6,2 (1.7) 5.8 ( l . l ) + 5,8 (0.8)
+p0.0l.++p0.055
There was a positive correlation between mean overnight Sa02 and measured use 
of NNV after 12 months (r = 0.70, p 0 .01) and a negative correlation between 
measured use of NNV and QOL (r ~ -0 .67). In the majority of patients the use of 
NNV increased over a period of 3 months, but subsequently decreased. Our data 
suggest that amelioration of nocturnal desaturation and QOL is sustained after 3 
months as long as compliance to NNV is maintained.
P2642
Perception of Reversibility
J.M. Donkers, C.P. van Schayck, R.P. Akkermans. (Department o f General 
Practice and Social Medicine, University o f Nijmegen)
Introduction: Patients with asthma or COPD often have a poor perception of 
changes in lung function (FEVj), In this study we investigated whether patients 
are able to perceive an increase in FEV | , after using bronchodilators. We also tried 
to distinguish determinants related to this perception.
Methods: Reversibility in FEVj was measured within 105 patients after 200 /¿g of 
salbutamol and 80 /xg ipratropiumbromide. Changes in dyspnoea were determined 
by a borgscore. Age, gender, allergy, age of onset, packyears and hyperrespon­
siveness are factors that might be related to the ability of perception and therefore 
investigated.
Results: The frequencies o f  patients who had an objective reversibility (AFEV| > 
= 9% of the predicted value, N ss 32) or no reversibility (AFEVj < 5%, N = 38) 
classified by change in dyspnoea are shown in the table,
N = 70 AI:EV| > 9 % A FEVj < 5% .
Decrease in dyspnoea 19 13
Equal dyspnoea 13 25
Of the patients who had an objective increase in FEV ], 59% perceived a decrease 
in dyspnoea. However, 34% of those with no (or little) increase in FEV|, also had 
decrease in dyspnoea. In the group of reversible patients, there was a significant 
difference in the number of housedust (mite) allergic patients between those who 
did or did not experience a decrease in dyspnoea (p <  0.05). The age of onset and 
the level of dyspnoea before medication also seemed to differ between perceivers 
and non-perceivers (p <  0.1). No differences were found in age, gender, packyears 
and hypcrresponsiveness between the two groups.
Conclusion: The majority o f  the reversible patients perceived a decrease in dysp­
noea, but 41% didn’t. Reversible patients with a decrease in dyspnoea seemed to 
perceive their dyspnoea as more serious, were younger at the start of the disease 
and were significantly more often allergic to housedust (mite).
P2643
Arc Changes in Dyspnea Perceived by Copd Patients Related to Changes in 
Lung Function: Terbutaline vs. Placebo
A. ten Brinke, L.L.J, van der Maas, E. Oostveen. Dpt. o f Pulmonology, Hospital 
Medisch Spectrum Twente, Enschede, The Netherlands
Many COPD patients report a relief of dyspnea sensation after administration 
of bronchodilators without showing important changes in FEVj. According to 
Noseda et al., Eur Respit J, 1993; 6: 636-644, the change in dyspnea mentioned 
by COPD patients is best related to the change in lung volume. Our objective 
was to determine the relationship between the subjective change in dyspnea and 
the objective change in lung function after bronchodilation in COPD patients. 
Methods: Twenty-two stable COPD outpatients (M/F: 16/6) aged 62 ±  8 yr. and 
baseline FEV| of 50 ±  13% pred. were included in our double blind cross-over 
designed study. All patients were seen on two separate occasions within one week 
and received either terbutaline (1 mg) or placebo inhalation in random order. After 
body plethysmographic determination of baseline lung function an inhalation was 
given. After ten minutes the change in dyspnea was rated with a bipolar Visual 
Analogue Scale (VAS) and measurement of lung function was repeated. Results: 
Terbutaline inhalation resulted in an improvement of dyspnea in 15 patients (VAS 
> +15%) while 9 out of the 22 patients improved after placebo inhalation.
Terbutaline Placebo
v a s  m +30(***) +20 (**)
A FEV! (L) +0.17 (***) -0 .13 <*)
A IVC (L) +0.25 (***) —0.04 (n.s.)
A TGV (L) -0 ,35  (♦**) +0,04 (n.s.)
A Rin (kPa.s/L) -0 .14  {*""*) +0,06 (*)
A Rex (kPa.s/L) -0 .39  (**) +0,16 ('*)
VAS and change of lung function in COPD patients nTter terbutaline or placebo inhalation (* 1,1111 
significant change from baseline p <  0.05,0.01,0.001, respectively (paired t-test))
There was no significant correlation between VAS and change in lung function 
after terbutaline inhalation. Excluding the non-perceivers from the analysis, a 
weak correlation was found between VAS and change in Rex (r = 0.50, p <  0.06). 
Conclusion; In contrast to previous suggestions we found no correlation between 
changes in sensation of dyspnea and lung function after inhalation of terbutaline 
in COPD patients.
P2644
Dyspnea Sensation in COPD. Physiological Determinants
P. de Lucas, J,M, Rodriguez Glez-Moro, J.M,a, Ruiz de Ofia, C. Rodriguez de 
Guzmdn, E, Tat ay, J.M. Cubillo, Servicio de Neumologia, HGU Gregorio 
Mara non, Madrid, Spain
Dyspnea sensation is one of the most common symptoms in COPD but its intensity 
is very among patients. The aim of this study was to assess the relationship between 
dyspnea and pulmonary and inspiratory muscle function impairment. We studied 
20 male patients with a previous diagnosis of COPD in a stable situation. In all 
patients we performed pulmonary function test (PFT), maximal inspiratory and 
expiratory pressure measurements (MIP, MEP), maximal symptom limited exercise 
test and submaximal constant exercise test. Dyspnea sensation was evaluated at the 
end of both exercise tests, using a Borg scale (B). The same studies were carried 
out after a 4 week period of inspiratory muscle training. All patients had a moderate 
to severe airflow obstruction (FEVl: 37.6 & 13%, FVC: 80.4 ±  15%, FRC: 140 
± 2 1 % , RV: 159.4 ±  14%) and a reduction in MIP (54 ±  9cmH20), We found a 
negative correlation between MIP and both maximal and submaximal exercise B 
before and after training. (In: PIM-Bmax: r 0.46 p < 0.05; PIM-Bsubmax r 0,57 
p <  0,01. Final: PIM-Bmax: r 0.56 p <  0.01; PIM-Bsubmax: r 0.73 p <  0.005). 
There was also a negative correlation between FEV 1 and initial B (FEVl-Bmax: r 
0.52; FEVl-Bsubmax r: 0.51; p <  0.05). Finally we found a negative correlation 
between changes in B and changes in FEVl*MIP (Bmax-PIM*FEVl r 0.56 p 
<  0.01; Bsubmax-Pim*FEVl r 0.53 p <  0.05). We conclude that, according to 
our results, the dyspnea sensation in COPD is related not only to the mechanical 
impairment but also to muscle capacity to cope with it. Therapeutical measures 
directed to improve muscle function may reduce the dyspnea sensation.
P2645
The Effect of Low Carbohydrate/High Fat Diet on Respiratory Function in 
Patients with Chronic Obstructive Pulmonary Disease (COPD)
S. U m ut1, G.A. T o s u n N .  Yildirim 1, R. Yticel2, G. §ahin2. 1 Dept o f  
Pulmonary Diseases, Istanbul University, Cerrahpa§a Medical Faculty, Istanbul, 
Turkey; 2 Dept o f Physiology, Istanbul University, Cerrahpa^a Medical Faculty, 
Istanbul, Turkey
The aim of the study was to evaluate the effect of low carbohydrate high fat 
diet in stable hypercapnic COPD patients. On the 1st and 15th days respiratory 
function tests were performed and 14 stable COPD patients entered the study. 
Activity of excess respiratory muscles were determined by electromyograms of 
sternocleidomastoid and external oblique muscles. Patients began a diet with low 
carbohydrate and high fat and were supported by 500 ml/day liquid diet which 
contained 16.7% protein, 55.2% fat, 28.1% carbohydrate, vitamins and minerals 
(Pulmocare). After 10 days of diet FVC increased (p <  0.05) and PaC02 decreased 
(p <  0.05). The activation time of both muscles decreased (p <  0.05) significantly.
423s
